KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VivoSim Labs (VIVS) EBT (2016 - 2025)

VivoSim Labs (VIVS) has 16 years of EBT data on record, last reported at -$2.7 million in Q4 2025.

  • For Q4 2025, EBT rose 21.93% year-over-year to -$2.7 million; the TTM value through Dec 2025 reached -$11.2 million, up 9.35%, while the annual FY2025 figure was -$12.5 million, 14.95% up from the prior year.
  • EBT reached -$2.7 million in Q4 2025 per VIVS's latest filing, down from -$2.5 million in the prior quarter.
  • Across five years, EBT topped out at -$1.9 million in Q1 2022 and bottomed at -$7.6 million in Q1 2023.
  • Average EBT over 5 years is -$3.3 million, with a median of -$3.2 million recorded in 2022.
  • Peak YoY movement for EBT: surged 60.82% in 2021, then crashed 297.8% in 2023.
  • A 5-year view of EBT shows it stood at -$3.5 million in 2021, then grew by 8.06% to -$3.2 million in 2022, then decreased by 12.06% to -$3.6 million in 2023, then grew by 4.36% to -$3.4 million in 2024, then increased by 21.93% to -$2.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$2.7 million in Q4 2025, -$2.5 million in Q3 2025, and -$2.8 million in Q2 2025.